News · eGov
Mumbai-based HaystackAnalytics is deploying next-generation sequencing across more than 40 Genomics Centres of Excellence to move infectious-disease diagnosis in India from detection to treatment-guiding intelligence.
✦ AI SUMMARY 30-second read
- HaystackAnalytics says its infexn-NGS platform delivers pan-bacterial, pan-fungal and respiratory-virus detection alongside antimicrobial resistance gene profiling from a single sample within 24 hours.
- The company's Genomics Centres of Excellence are accessed by 650-plus hospitals and labs and more than 2,500 doctors, with partners including Max Hospitals, Lilavati Hospital and Government Medical College networks.
- An investment of approximately $30 million is being sought over the next three years to fund product development, infrastructure and international expansion into the US and UK markets.
Why it matters: India carries roughly 26 per cent of global TB cases and 32 per cent of global MDR/RR-TB cases, making faster, resistance-aware diagnostics a national priority.
This summary was generated by AI. Editors may review and update it.
HaystackAnalytics, a genomics-focused diagnostics company, is scaling a network of Genomics Centres of Excellence across India to bring culture-free, next-generation sequencing-based infectious-disease testing closer to patients and clinical teams.
The company's co-founders, Gaurav Srivastava and Dr Anirvan Chatterjee, have outlined a strategy that spans TB drug-resistance profiling, hospital-acquired infection surveillance and a planned international push into the US and UK over the next 24 months.
The expansion comes against a backdrop of growing antimicrobial resistance pressure in India, where diagnostic uncertainty often drives empirical broad-spectrum antibiotic use before a pathogen or its resistance profile is confirmed.
What the technology does
The company's flagship platform, infexn-NGS, combines targeted sequencing with advanced bioinformatics to detect a broad range of bacterial, fungal and viral pathogens from a single clinical sample, returning results within 24 hours without requiring culture.
The platform simultaneously identifies key antimicrobial resistance genes, giving clinicians information on both the infectious agent and its potential resistance profile in a single test run.
For TB specifically, HaystackAnalytics says its solution can report directly from sputum, covering drug-susceptibility information across 18 anti-TB drugs and 37 resistance gene targets, along with mixed-infection detection.
The GCE partnership model
Rather than asking hospitals to build independent sequencing infrastructure, HaystackAnalytics introduced the Genomics Centre of Excellence model, which allows hospitals and diagnostic laboratories to integrate genomic testing into existing workflows.
The network currently spans more than 40 GCEs and is accessed by more than 650 hospitals and labs and more than 2,500 doctors. Named institutional partners include Max Hospitals, Lilavati Hospital, HN Reliance Foundation Hospital, Bombay Hospital and Government Medical College networks.
Srivastava described the next phase as deepening clinical relevance and broadening access across diverse healthcare settings, with international partnership discussions already underway, including with the NHS.
Funding and growth plans
The company is seeking approximately $30 million over the next three years to support product development, technology and infrastructure strengthening, distribution network expansion in India and accelerated entry into international markets.
Srivastava said the company is in advanced conversations with potential capital partners and is engaging with healthcare organisations including Sun Pharma and Alkem, among others.
For FY26–27, the stated focus is on accelerating adoption in India while establishing the regulatory and clinical partnerships needed for a market-by-market international entry strategy.
TB and the national elimination agenda
Dr Chatterjee noted that India accounts for roughly 26 per cent of global TB cases and 32 per cent of global MDR/RR-TB cases, making drug resistance central rather than peripheral to the country's TB burden.
He argued that the most important shift needed in TB diagnostics is the move from detection alone to comprehensive, timely and reliable insights that can actively guide treatment choices, reducing reliance on prolonged empirical therapy.
Genomics, he said, has the potential to bridge diagnosis and therapy by providing the depth of resistance information clinicians need to make more precise, evidence-led decisions earlier in the patient journey.